Drug intelligence / Profile preview

Ab-14-SA-PSSM1

Development stage: Preclinical
Lead developer: Keck Graduate Institute
Modality: Antibody-Based Therapeutics

Overview

Ab-14-SA-PSSM1 is a computationally designed variant antibody optimized using the Ab-Affinity large language model (LLM) in combination with genetic algorithms and simulated annealing. It is designed to target a specific epitope on the SARS-CoV-2 spike protein with high affinity and stability. The antibody is expressed in *Pichia pastoris* and is being experimentally validated for its binding affinity and neutralization potential against SARS-CoV-2.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Ab-14-SA-PSSM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ab-14-SA-PSSM1.